Health

CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, ...

2025-01-13 21:50 1099

CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion

-  R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms -  Financing will accelerate Mirxes, Singapore -based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets -  Transacti...

2025-01-13 19:25 1887

XingImaging Opens State-of-the-Art Research Facility in New Haven, Connecticut

NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven, Connecticut. The facility includes a clinic to recrui...

2025-01-13 18:00 900

CTF Life Becomes Title Sponsor of "Fencing Plus" Training Programme by Kai Tak Sports Initiative Nurturing a New Generation of Sports Elites for Hong Kong Gearing Up for World Championships

HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Chow Tai Fook Life Insurance Company Limited (CTF Life) is pleased to become the Title Sponsor of "Fencing Plus" Training Programme by Kai Tak Sports Initiative, cultivating a new generation of elite fencing athletes for Hong Kong as future world champions...

2025-01-13 16:57 2132

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended31 December 2024 (Q4 2024). Sustained revenue growth * Q...

2025-01-13 15:12 1804

Scintimun® Commercialization Partnership with Curium Pharma

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99m Tc-be...

2025-01-13 13:08 1304

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successful...

2025-01-13 09:05 2435

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successful...

2025-01-13 09:05 2038

WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Suppl...

2025-01-13 08:00 1665

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next...

2025-01-13 06:34 1886

Neusoft Education officially renamed as " Neutech Group Limited ", accelerating the advancement of the "education-healthcare-wellness and mind tour" strategy in a new stage

HONG KONG, Jan. 11, 2025 /PRNewswire/ -- On 9 January, Neusoft Education (09616.HK) announced that the Company's English name will change from "Neusoft Education Technology Co. Limited" to "Neutech Group Limited". The name change will take effect on the same day. According to the announcement, t...

2025-01-12 15:14 2752

Duke-NUS marks 20 years with transformative S$30m in philanthropic gifts and pledges to boost next-gen medical breakthroughs

* The legacy of Duke-NUS' founding donor, the Estate of Khoo Teck Puat, continues with a transformativeS$5.5 million gift towards research. * The HEAD Foundation steps up with a S$200,000 scholarship, underpinning Duke-NUS' commitment to developing medical expertise. SINGAPORE, Jan. 11, 2025 ...

2025-01-11 22:15 3438

Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).

CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited  ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agr...

2025-01-11 17:07 4054

Corn Next Launches CornNext-17: A Groundbreaking Sustainable Solution to Plastic Pollution

IRVINE, Calif., Jan. 11, 2025 /PRNewswire/ -- Corn Next, a leader in sustainable innovation and biodegradable solutions, has officially launched CornNext-17, a game-changing bio-based material designed to combat the global plastic pollution crisis. Accompanying this launch is the release of th...

2025-01-11 05:53 4182

Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity

* Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau * No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo * Enrollment o...

2025-01-11 01:30 2107

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...

2025-01-11 00:00 2263

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...

2025-01-10 22:00 1559

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immuno...

2025-01-10 21:01 3616

Psylo Rebrands as Xylo, with Key Board Appointments and Breakthrough Pipeline Progress

Announces Major Milestones at the JPM Healthcare Conference SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded asXylo Bio . This transformation reflects the company's growth, sharpened focus ...

2025-01-10 21:00 992

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Adm...

2025-01-10 17:00 4064
12345 ... 871